Mirum Pharmaceuticals, Inc. (MIRM) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Foster City, CA, United States. The current CEO is Christopher Peetz.
MIRM has IPO date of 2019-07-18, 334 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $4.86B.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing novel therapies for rare and orphan diseases affecting the liver and bile system. The company's lead product candidate, LIVMARLI, is an investigational oral medication designed to treat progressive familial intrahepatic cholestasis, Alagille syndrome, and biliary atresia. Mirum also develops Volixibat for the treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018 and headquartered in Foster City, California, Mirum focuses on addressing critical unmet needs in hepatobiliary diseases.
